See more : NICE Ltd. (NICE) Income Statement Analysis – Financial Results
Complete financial analysis of Prestige BioPharma Limited (950210.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prestige BioPharma Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Solitaire Machine Tools Limited (SOLIMAC.BO) Income Statement Analysis – Financial Results
- Ratch Group Public Company Limited (RATCH.BK) Income Statement Analysis – Financial Results
- Instone Real Estate Group SE (0ZQ7.L) Income Statement Analysis – Financial Results
- FTI Consulting, Inc. (FCN) Income Statement Analysis – Financial Results
- Kinetic Group Inc. (KNIT) Income Statement Analysis – Financial Results
Prestige BioPharma Limited (950210.KS)
About Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 689.08M | 161.84M | 0.00 | 0.00 | 0.00 | 2.09B | 0.00 |
| Cost of Revenue | 0.00 | 11.66B | 3.87B | 1.67B | 1.19B | 755.33M | 240.24M |
| Gross Profit | 689.08M | -11.50B | -3.87B | -1.67B | -1.19B | 1.33B | -240.24M |
| Gross Profit Ratio | 100.00% | -7,103.88% | 0.00% | 0.00% | 0.00% | 63.84% | 0.00% |
| Research & Development | 0.00 | 40.91B | 17.71B | 10.13B | 4.20B | 2.32B | 1.37B |
| General & Administrative | 17.20B | 28.72B | 24.26B | 600.86M | 1.15B | 0.00 | 0.00 |
| Selling & Marketing | 12.69B | 10.88B | 18.59B | 8.71B | 5.05B | 0.00 | 0.00 |
| SG&A | 29.90B | 39.60B | 42.85B | 9.31B | 6.20B | 3.42B | 1.63B |
| Other Expenses | 33.57B | 73.48B | 15.67B | 9.07B | 4.67B | 0.00 | 0.00 |
| Operating Expenses | 63.47B | -905.40M | 58.52B | 18.38B | 10.87B | 5.74B | 3.00B |
| Cost & Expenses | 63.47B | -905.40M | 58.52B | 18.38B | 10.87B | 6.49B | 3.24B |
| Interest Income | 12.40B | 10.46B | 2.73B | 158.22M | 523.21M | 221.21M | 15.26M |
| Interest Expense | 7.40B | 950.80M | 18.85M | 6.20M | 0.00 | 0.00 | 249.33K |
| Depreciation & Amortization | 16.27B | 11.66B | 3.87B | 1.67B | 1.19B | 573.68M | 240.24M |
| EBITDA | -31.05B | 10.51B | -206.91B | -5.68B | -13.72B | -686.47M | -1.99B |
| EBITDA Ratio | -4,505.69% | 15,494.36% | 0.00% | 0.00% | 0.00% | -183.36% | 0.00% |
| Operating Income | -62.78B | -69.57B | -58.52B | -18.38B | -10.87B | -4.40B | -3.24B |
| Operating Income Ratio | -9,111.19% | -42,988.30% | 0.00% | 0.00% | 0.00% | -210.82% | 0.00% |
| Total Other Income/Expenses | 8.09B | 67.48B | -152.28B | 11.03B | -4.03B | 3.14B | 1.01B |
| Income Before Tax | -54.69B | -2.10B | -210.65B | -7.36B | -14.90B | -1.26B | -2.23B |
| Income Before Tax Ratio | -7,936.63% | -1,294.78% | 0.00% | 0.00% | 0.00% | -60.32% | 0.00% |
| Income Tax Expense | 408.68M | 763.28M | 800.66M | 34.08M | 98.47M | 187.34M | -2.00 |
| Net Income | -32.92B | 17.57B | -211.45B | -7.39B | -15.00B | -1.45B | -2.23B |
| Net Income Ratio | -4,777.60% | 10,855.89% | 0.00% | 0.00% | 0.00% | -69.29% | 0.00% |
| EPS | -547.81 | 292.35 | -3.52K | -135.99 | -49.91 | -4.82 | -7.42 |
| EPS Diluted | -547.81 | 292.35 | -3.52K | -135.99 | -49.91 | -4.82 | -7.42 |
| Weighted Avg Shares Out | 60.10M | 60.10M | 60.10M | 54.35M | 300.48M | 300.48M | 300.48M |
| Weighted Avg Shares Out (Dil) | 60.10M | 60.10M | 60.10M | 54.35M | 300.48M | 300.48M | 300.48M |
Source: https://incomestatements.info
Category: Stock Reports